Compare Illumina, Inc. (ILMN) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Johnson Controls International PLC — how do they compare? Illumina, Inc. trades at $275.1 (market cap $39.95B), while Johnson Controls International PLC trades at $157.97 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 2.3× Illumina, Inc.'s market cap, and Johnson Controls International PLC pays a 1.04% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Johnson Controls International PLC for 65 Days on average.
| ILMN | JCI | |
|---|---|---|
Market Cap | $39.95B | $93.28B |
Volume | 3,169,503 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $293.69 | $158.76 |
52-Week Low | $91.00 | $105.55 |
Typical Hold Time | 83 Days | 65 Days |
Enterprise Value | $41.31B | $102.12B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Johnson Controls International (JCI) trades at $157.46, up 0.98% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.42 versus $1.30 expected, and revenue growth accelerating to 9% in Q3 2026. Valuation metrics remain elevated with P/E at 43.38, but profitability is strong with net income margin of 14.32% and ROE of 24.42%.
JCI presents a favorable investment case with consistent earnings beats, raised FY26 guidance, and strong institutional support. Key risks include high valuation multiples and increasing debt-to-asset ratio reaching 26.06% in 2025. The consensus price target of $172.50 suggests 9.6% upside potential from current levels, supported by 28 buy ratings and no sell recommendations from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
